REG - Cambridge Cognition - Formation of new Scientific Advisory Board

Cambridge Cognition HoldingsAnnouncement

21/03/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240321:nRSU6770Ha&default-theme=true

RNS Number : 6770H  Cambridge Cognition Holdings PLC  21 March 2024

 

21 March 2024

 

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

 

Cambridge Cognition announces formation of new Scientific Advisory Board

 

Cambridge Cognition Holdings plc (AIM: COG), which develops and markets
digital solutions to assess brain health, is pleased to announce the formation
of a Scientific Advisory Board.

 

This expert board will provide scientific guidance and valuable market
insights, primarily focusing on addressing emerging trends such as the
integration of blood-based biomarkers, the collaborative possibilities for
computerised cognitive assessments, and the benefits of diverse populations
and patient meaningfulness for clinical trials. It will also review and advise
on product strategies, scientific approaches, and evidence-generation for
regulatory and data strategies.

 

The advisory board combines expertise covering CNS-related disorders, clinical
development, and academia with a shared dedication to propelling brain health
forward. With a wealth of experience in clinical development programmes, the
board will support Cambridge Cognition in exploiting market trends effectively
and ensuring its services and technologies continually adapt within the
intricate and changing landscape for life science companies.

 

The Scientific Advisory Board is chaired by Liam Kaufman, Vice President of
Clinical Science and former CEO of Winterlight Labs, and is comprised of three
founding members, highly qualified experts, namely:

·      Professor Judith Jaeger, PhD, who serves as owner and president
of CognitionMetrics, LLC

·      Professor John Harrison, Chief Scientific Officer at Scottish
Brain Sciences

·      Francesca Cormack, PhD, Chief Scientist at Cambridge Cognition

 

Professor Judith Jaeger is a neuropsychologist with over 35 years of
experience in clinical and experimental neuropsychology and psychopathology.
She is the owner and president of CognitionMetrics, LLC, a consultancy serving
the pharmaceutical industry on early-phase and experimental medicine projects
and pivotal and late-phase clinical programmes in CNS-affected diseases. She
has represented pharmaceutical clients in regulatory meetings, including the
FDA and Japan's PMDA. She is a Clinical Professor of Psychiatry and Behavioral
Science at Albert Einstein College of Medicine, New York. She has authored
over 90 peer-reviewed journal articles, several book chapters, co-edited books
and hundreds of abstracts and presentations. Previously, she was Vice
President for Clinical Trials at Cogstate, Inc. and Director of Clinical
Development at AstraZeneca Pharmaceuticals, where she served as company-wide
cognition and psychometrics expert. These industry positions followed a
distinguished academic career as an NIH-funded research clinician and
educator.

 

Professor John Harrison is an acknowledged cognition expert whose principal
professional interest is in helping people understand, maintain, and enhance
their cognitive skills. John is Chief Scientific Officer at Scottish Brain
Sciences, a clinical trial and neuroscientific research company. In the past
25 years, John has assisted more than 80 CNS drug development organisations
with selecting and successfully integrating cognitive testing into therapeutic
development programmes. His work in Alzheimer's disease dates back to his
participation in the studies of compound AN1792, for which he developed the
Neuropsychological Test Battery (NTB). Variants of the NTB have since been a
common feature of CNS-focused treatment development programmes. Work in
psychiatric indications has included a key role in the development and
registration of Brintellix. John is an associate professor at the AUmc
Alzheimer Center and a visiting professor at King's College London. He holds
Chartered Psychologist status and has authored/co-authored more than 100 books
and scientific articles.

 

 

Matthew Stork, Chief Executive Officer of Cambridge Cognition, commented:

 

"With the emergence of disease-modifying therapies for Alzheimer's disease and
progress in many other conditions, as well as the evolution of digital
cognitive assessments, the landscape for CNS clinical research is rapidly
evolving. Establishing the Scientific Advisory Board underscores our
dedication to advancing the alignment of emerging trends in the sector. The
board aims to deepen our understanding of customer requirements, assisting us
to adapt rapidly to the evolving landscape while expanding the capabilities of
our solutions."

 

Professor Judith Jaeger, PhD, commented:

 

"I'm delighted to have joined the Cambridge Cognition SAB and look forward to
supporting the company's application of 30 years of cognitive science, plus
the added value of Winterlight Labs' capabilities, to facilitate
decision-making in developing new therapeutics affecting cognition. I am eager
to contribute to Cambridge Cognition's continued growth in 2024 and beyond."

 

Professor John Harrison, commented:

 

 "I have more than 30 years' experience with the CANTAB system, first as a
user, and between 1997 and 2000 as one of the team working on its development
and validation. I have also had the good fortune to have worked with the
Winterlight Labs team on their technology, which I regard as one of the most
promising in the digital cognitive assessment space. It is, therefore, a huge
pleasure to have the opportunity to shape the use and future development of
these technologies as part of the Cambridge Cognition Scientific Advisory
Board."

 

Enquiries:

 

 Cambridge Cognition Holdings plc                         Tel: 012 2381 0700

 Matthew Stork, Chief Executive Officer                   press@camcog.com (mailto:press@camcog.com)

 Stephen Symonds, Chief Financial Officer

 Panmure Gordon (UK) Limited (NOMAD and Joint Broker)     Tel: 020 7886 2968

 Freddy Crossley / Emma Earl                              (Corporate Finance)

 Rupert Dearden                                           (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)                   Tel: 020 3903 7715

 David Poutney / James Serjeant

 Hudson Sandler (Financial PR and IR)                     Tel: 020 7796 4133

 Dan de Belder / Hattie Dreyfus                           cog@hudsonsandler.com (mailto:cog@hudsonsandler.com)

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a technology company developing digital health products
to better understand, detect and treat conditions affecting brain health. The
Company's software products assess cognitive health in patients worldwide to
improve clinical trial outcomes, identify and stratify patients early and
improve global efficiency in pharmaceutical and healthcare industries.

 

For further information visit

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDQKKBBOBKDKNB